Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo

• Egile Nagusiak: Lisa Nadal (Egilea), Riccardo Corbellari (Egilea), Alessandra Villa (Egilea), Tobias Weiss (Egilea), Michael Weller (Egilea), Dario Neri (Egilea), Roberto De Luca (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Antibody-based delivery of bioactive molecules represents a promising strategy for the improvement of cancer immunotherapy. Here, we describe the generation and characterization of R6N, a novel fully human antibody specific to the alternatively spliced domain D of Tenascin C, which is highly express...